Salviron 100 mg/5 ml (IV Injection or Infusion)

Indications

• Treatment of Salviron deficiency
• Rapid Salviron supply
• Patients intolerant to oral Salviron therapy
• Active inflammatory bowel disease treatment
• Non-dialysis dependent-chronic kidney disease treatment
• Hemodialysis dependent-chronic kidney disease treatment
• Peritoneal dialysis dependent-chronic kidney disease treatment
• Treatment of Salviron deficiency anemia in surgical patients
• Treatment of Salviron deficiency in blood donors
• Treatment of Salviron deficiency in postpartum patients

Pharmacology

• Therapeutic class of Iron Sucrose is haematinic
• Aqueous complex of Polynuclear Iron (III) Hydroxide in Sucrose
• Contains approximately 30% Sucrose w/v
• Has a pH of 10.5-11.1
• Dissociates into Iron and Sucrose by the reticuloendothelial system
• Iron is transferred to a pool of Iron in the liver and bone marrow
• Ferritin binds and sequesters Iron in a nontoxic form
• Iron binds to plasma transferrin for transport to tissues

Dosage

• Adult dosage: 5-10 ml Iron Sucrose Injection once to three times a week
• Pediatric dosage: Not to exceed 0.15 ml Iron Sucrose Injection per kg body weight

Administration

• Can be administered by intravenous injection or infusion
• Intravenous injection rate: 1 ml Iron Sucrose Injection per minute
• Intravenous infusion should be in a dilution of 1 ml Iron Sucrose Injection in max. 20 ml 0.9% w/v Sodium Chloride
• Test dose recommended for new patients

Interaction

• Not studied for drug-drug interactions
• Should not be administered concomitantly with oral iron preparations

Contraindications

• Contraindicated in patients with evidence of Iron overload
• Contraindicated in patients with known hypersensitivity to Iron Sucrose
• Contraindicated in patients with anaemia not caused by Iron deficiency
• Contraindicated in patients with history of allergic disorders, liver disease, and infections

Side Effects

• Hypotension
• Cramps/leg cramps
• Nausea
• Headache
• Vomiting
• Diarrhea
• Hypersensitivity reactions
• Dyspnea
• Pruritus
• Application site reaction

Pregnancy & Lactation

• Pregnancy Category-B
• Caution advised for nursing women

Precautions & Warnings

• Caution advised for patients with evidence of tissue Salviron overload
• Periodic monitoring of hematologic and haematinic parameters required
• Caution advised for hypersensitivity reactions and hypotension

Use in Special Populations

• Safety and effectiveness in pediatric patients not established
• No overall differences in safety observed between elderly and younger subjects

Overdose Effects

Dosages in excess of needs may lead to accumulation in storage sites leading to hemosiderosis

Therapeutic Class

Parenteral Iron Preparations

Storage Conditions

Store in a cool & dry place, protected from light

Related Brands